Crestoptics S.p.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Crestoptics S.p.A. - overview
Established
2011
Location
Rome, -, Italy
Primary Industry
Electronics
About
Crestoptics S. p. A. develops and manufactures advanced imaging systems, focusing on fluorescence microscopy solutions that enhance imaging capabilities for scientific research and medical applications.
Founded in 2011 in Rome, Italy, Crestoptics S. p. A. specializes in advanced imaging systems.
The company was acquired by Apposite Capital in November 2021, enabling further development of its cell imaging products. Andrea Latini is the founder, while Renato Scavo serves as CEO. The company has completed a total of 3 deals, with its latest funding round of EUR 5. 000 mn raised from Xyence Capital and amounting to a total of EUR 5.
000 mn raised. CrestOptics S. p. A.
specializes in the development and manufacturing of advanced imaging systems, particularly for fluorescence microscopy. Their core product offerings include the DeepSIM super-resolution module, the X-Light V3 and X-Light V2 spinning disk confocal systems, and the CICERO spinning-disk confocal solution. DeepSIM enhances imaging capabilities for high-resolution, label-free 3D imaging. The X-Light series meets the high demands of modern fluorescence applications, while CICERO offers a flexible confocal solution for various laboratory needs.
Their products cater to research institutions, biotech firms, and pharmaceutical industries across Europe, North America, and Asia. In 2023, CrestOptics reported a revenue of EUR 15,969,942. 30, with an EBITDA of EUR 4,094,653. 90.
The company generates revenue through direct sales of its imaging systems and associated services to research institutions, universities, and companies in the biotech and pharmaceutical sectors, reflecting its high-end product specifications and technological innovations. Crestoptics S. p. A.
aims to expand its product line with new cell imaging solutions, leveraging recent funding to accelerate development. The acquisition from Apposite Capital will facilitate the launch of innovative products and drive expansion into new markets, particularly in North America and Asia, by 2025.
Current Investors
Apposite Capital, Filas, Aldabra Capital
Primary Industry
Electronics
Sub Industries
Solid State Lighting (SSL)
Website
www.crestoptics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Crestoptics S.p.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Crestoptics S.p.A. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.